Achieved a critical regulatory milestone with FDA approval of the Biologics License Application (BLA) for Avance, establishing it as the first and only approved biologic therapeutic for peripheral nerve discontinuities. Delivered 20.2% full-year revenue growth driven by double-digit expansion across all three target markets: Extremities, Oral Maxillofacial, and Breast. Reached a financial inflection point characterized by positive cash flow and improved profitability, enabling concentrated market deve ...

monoclonal antibodies. In addition, CD73 activity has been shown to promote angiogenesis, including through upregulation of VEGF signaling, and may contribute to the development of resistance to anti-VEGF therapies. Given the broad relevance of immune suppression, angiogenesis and adenosine signaling across solid tumors, this combination strategy has the potential to be applicable across multiple tumor types. Taken together, these observations suggest that combining CD73 blockade with PD-1/VEGF-directed app ...

New York, New York--(Newsfile Corp. - February 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

The S&P 500 (SNPINDEX:^GSPC) rose 0.78% to 6,891.04, the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 1.04% to 22,863.68, and the Dow Jones Industrial Average (DJINDICES:^DJI) added 0.76% to 49,174.49 as AI jitters eased. Market movers Biotech player Iovance Biotherapeutics jumped 32% on positive sarcoma trial data, while Advanced Micro Devices climbed on reports of a new AI chip deal with Meta Platforms. In staples, J.M. Smucker outperformed after a Bank of America upgrade, while General Mills lagged aft ...

AbCellera Biologics (NasdaqGS:ABCL) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsAndrew Booth - CFOCarl Hansen - President and CEOMalcolm Hoffman - VP of BioPharma Equity ResearchSarah Noonberg - Chief Medical OfficerStephen Willey - Managing Director of HealthcareTryn Stimart - Chief Legal and Compliance OfficerConference Call ParticipantsAllison Bratzel - VP and Senior Research AnalystBrendan Smith - Director and Senior Analyst for Life Science Tools and Diagnostics/Biotechnolog ...

AbCellera Biologics (NasdaqGS:ABCL) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsAndrew Booth - CFOCarl Hansen - President and CEOMalcolm Hoffman - VP of BioPharma Equity ResearchSarah Noonberg - Chief Medical OfficerStephen Willey - Managing Director of HealthcareTryn Stimart - Chief Legal and Compliance OfficerConference Call ParticipantsAllison Bratzel - VP and Senior Research AnalystBrendan Smith - Director and Senior Analyst for Life Science Tools and Diagnostics/Biotechnolog ...

Nektar Therapeutics to Participate in Two Investor Conferences in March [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami.- 2026 Jefferies Biotech on the Beach Summit in Miami – March 9-11, 2026 – co ...

AbCellera Biologics (NasdaqGS:ABCL) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Speaker4Good afternoon, and welcome to AbCellera's full year 2025 business update conference call. My name is Chelsea, and I will facilitate the audio portion of today's interact. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, press star one again. At this time, I would like to turn ...

PresentationOperator Hello, and welcome to the Protara Therapeutics ASCO GU Update Call. [Operator Instructions] As a reminder, this conference call is being recorded. If you have any objections, please disconnect at this time. With that, I would now like to turn the call over to Justine O'Malley, Senior Vice President, Investor Relations and Corporate Affairs. ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 辽宁成大生物股份有限公司（以下简称"公司"）全资子公司成大生物（本溪）有限公司（以下简称"本 溪子公司"）于近日收到国家药品监督管理局签发的冻干人用狂犬病疫苗（人二倍体细胞）（以下简 称"人用二倍体狂犬疫苗"）《药品注册证书》。现将相关情况公告如下： 药品批准文号：国药准字S20260012 药品批准文号有效期：至2031年02月09日 上市许可持有人：成大生物（本溪）有限公司 生产企业：成大生物（本溪）有限公司 证书编号：2026S00502 一、药品基本情况 药品名称：冻干人用狂犬病疫苗（人二倍体细胞） 剂型：注射剂 规格：按标示量复溶后每瓶1.0ml。每1次人用剂量为1.0ml，狂犬病疫苗效价应不低于2.5IU。 批准事项：药品注册（境内生产） 注册分类：预防用生物制品 三、对公司的影响 辽宁成大生物股份有限公司 本次本溪子公司人用二倍体狂犬疫苗获批上市，将进一步完善公司疫苗产品布局，增强核心竞争力，巩 固在狂犬病疫苗领 ...